Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early rheumatoid arthritis trial comparing active conventional therapy with biologic strategies and de-escalation
2024-516723-14-00Phase 4Authorised
- Sponsor
- Karolinska Institutet
- Start
- Sep 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, open-label trial of methotrexate, abatacept, certolizumab pegol, tocilizumab, hydroxychloroquine and 6 more in rheumatoid arthritis (RA) (4 arms), sponsored by Karolinska Institutet. Planned start Sep 2026; status: authorised.
02
Drugs
methotrexateabataceptcertolizumab pegoltocilizumabhydroxychloroquine
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-516723-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516723-14-00.